Researchers identified elevated CD93 expression as a correlate of immunosuppression and reduced response to immunotherapy in advanced non-small cell lung cancer. Integrated database analyses and specimen validation suggested CD93 is linked to immune context shifts, including lower CD8 presence and higher FOXP3 signals. The study also reported that patients with high CD93 expression tended to show poorer pathological response to immunotherapy, supporting biomarker development hypotheses tied to tumor microenvironment modulation. For biotech teams, the practical question becomes biomarker implementation—whether CD93 can be measured reliably in clinical workflows and whether it adds incremental value over existing predictive signatures.